Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00565370

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

A Phase I-II Study of Sorafenib (Nexavar®) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer

Sponsor: Asan Medical Center

Conditions Advanced Gastric Cancer

Interventions Capecitabine, Cisplatin, Sorafenib

Updated 10 times since 2017 Last updated: Jan 6, 2020 Started: Nov 30, 2007 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00565370, this PHASE1/PHASE2 trial focuses on Advanced Gastric Cancer and remains completed. Sponsored by Asan Medical Center, it has been updated 10 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2

▶ Show 5 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Feb 2020 [monthly]

Completed PHASE1_PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Sep 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asan Medical Center

Data source: Asan Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea